Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
Chandler Gandy,1 Shadi Bazzazzadehgan,1 Sebastian Bruera,2 Yinan Huang1 1Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, 38677 USA; 2Section of Immunology, Allergy & Rheumatology, Baylor College of Medicine, Houston, TX, USACorrespondence: Yin...
Saved in:
Main Authors: | Gandy C, Bazzazzadehgan S, Bruera S, Huang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Drug, Healthcare and Patient Safety |
Subjects: | |
Online Access: | https://www.dovepress.com/evaluation-of-real-world-evidence-to-assess-effectiveness-outcomes-of--peer-reviewed-fulltext-article-DHPS |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
by: Peter Youssef, et al.
Published: (2025-01-01) -
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01) -
Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01) -
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?
by: Beatrice Maranini, et al.
Published: (2025-01-01)